drugset / Trial / NCT07422558

Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain

NCT07422558

Not yet recruiting 92 enrolled Hayatabad Medical Complex
RandomizedParallel-groupSingle-blindPrevention

Summary

Propofol is a commonly used intravenous anesthetic agent, but its administration is frequently associated with injection pain, causing patient discomfort and agitation. Various pharmacological agents have been used to reduce this pain, including nalbuphine and lidocaine; however, results from previous studies remain conflicting. This randomized clinical trial aims to compare the effectiveness of intravenous nalbuphine versus intravenous lidocaine in reducing the frequency of propofol-induced injection pain in patients undergoing elective general surgery procedures.

Timeline

Start
2026-03-01
Primary completion
2026-08-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 4.5 mg/kg Intravenous
Subject Nalbuphine Small molecule 0.1 mg/kg Intravenous

Indications

No indication recorded.